Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 27:14:1118653.
doi: 10.3389/fphys.2023.1118653. eCollection 2023.

Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV

Yashvardhan Batta  1 , Cody King  1 , Farion Cooper  1 , John Johnson  2 , Natasha Haddad  1 , Myriam G Boueri  3 , Ella DeBerry  1 , Georges E Haddad  1
Affiliations
Review

Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV

Yashvardhan Batta et al. Front Physiol. .

Abstract

With reports of its emergence as far back as the early 1900s, human immunodeficiency virus (HIV) has become one of the deadliest and most difficult viruses to treat in the era of modern medicine. Although not always effective, HIV treatment has evolved and improved substantially over the past few decades. Despite the major advancements in the efficacy of HIV therapy, there are mounting concerns about the physiological, cardiovascular, and neurological sequelae of current treatments. The objective of this review is to (Blattner et al., Cancer Res., 1985, 45(9 Suppl), 4598s-601s) highlight the different forms of antiretroviral therapy, how they work, and any effects that they may have on the cardiovascular health of patients living with HIV, and to (Mann et al., J Infect Dis, 1992, 165(2), 245-50) explore the new, more common therapeutic combinations currently available and their effects on cardiovascular and neurological health. We executed a computer-based literature search using databases such as PubMed to look for relevant, original articles that were published after 1998 to current year. Articles that had relevance, in any capacity, to the field of HIV therapy and its intersection with cardiovascular and neurological health were included. Amongst currently used classes of HIV therapies, protease inhibitors (PIs) and combined anti-retroviral therapy (cART) were found to have an overall negative effect on the cardiovascular system related to increased cardiac apoptosis, reduced repair mechanisms, block hyperplasia/hypertrophy, decreased ATP production in the heart tissue, increased total cholesterol, low-density lipoproteins, triglycerides, and gross endothelial dysfunction. The review of Integrase Strand Transfer Inhibitors (INSTI), Nucleoside Reverse Transcriptase Inhibitors (NRTI), and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) revealed mixed results, in which both positive and negative effects on cardiovascular health were observed. In parallel, studies suggest that autonomic dysfunction caused by these drugs is a frequent and significant occurrence that needs to be closely monitored in all HIV + patients. While still a relatively nascent field, more research on the cardiovascular and neurological implications of HIV therapy is crucial to accurately evaluate patient risk.

Keywords: HIV; Neurology; cardiometabolic dysfunction; cardiovascular disease; combined anti-retroviral treatment (cART); highly active anti-retroviral therapy (HAART).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
HIV pharmacological targets.
FIGURE 2
FIGURE 2
Combined Graphic of action of all cART drug classes.
See this image and copyright information in PMC

References

    1. Antony I., Kannichamy V., Banerjee A., Gandhi A. B. (2020). An outlook on the impact of HIV infection and highly active antiretroviral therapy on the cardiovascular system - a review. Cureus 12 (11), e11539. 10.7759/cureus.11539 - DOI - PMC - PubMed
    1. Askgaard G., Kristoffersen U. S., Mehlsen J., Kronborg G., Kjaer A., Lebech A. M. (2011). Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: Importance of blood glucose and cholesterol. PLoS One 6 (5), e20196. 10.1371/journal.pone.0020196 - DOI - PMC - PubMed
    1. Banda N. K., Bernier J., Kurahara D. K., Kurrle R., Haigwood N., Sekaly R. P., et al. (1992). Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. 176 (4), 1099–1106. 10.1084/jem.176.4.1099 - DOI - PMC - PubMed
    1. Bavinger C., Bendavid E., Niehaus K., Olshen R. A., Olkin I., Sundaram V., et al. (2013). Risk of cardiovascular disease from antiretroviral therapy for HIV: A systematic review. PLoS One 8 (3), e59551. 10.1371/journal.pone.0059551 - DOI - PMC - PubMed
    1. Bedimo R. J., Westfall A. O., Drechsler H., Vidiella G., Tebas P. (2011). Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin. Infect. Dis. 53 (1), 84–91. 10.1093/cid/cir269 - DOI - PubMed